Skip to content
ETopical – Lifestyle
Home
Sample Page
Author:
Polaryx Therapeutics, Inc.
Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial
May 28, 2026
Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards
May 14, 2026
Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference
April 23, 2026
Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial
April 21, 2026
Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care
April 15, 2026
Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference
April 1, 2026
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)
March 17, 2026
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events
March 12, 2026